• 1
    Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338: 17411751.DOI: 10.1056/NEJM199806113382407
  • 2
    Paya CV. Indirect effects of CMV in the solid organ transplant patient. Transpl Infect Dis 1999; 1(Suppl. 1): 812.
  • 3
    Stratta RJ. Clinical patterns and treatment of cytomegalovirus infection after solid-organ transplantation. Transplant Proc 1993; 25(5 Suppl. 4): 1521.
  • 4
    Portela D, Patel R, Larson-Keller JJ et al. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. J Infect Dis 1995; 171: 10141018.
  • 5
    Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995; 346: 6974.DOI: 10.1016/S0140-6736(95)92110-9
  • 6
    Gane E, Saliba F, Valdecasas GJ et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver transplant recipients. Lancet 1997; 350: 17291733.DOI: 10.1016/S0140-6736(97)05535-9
  • 7
    Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611620.DOI: 10.1111/j.1600-6143.2004.00382.x
  • 8
    Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 10941097.DOI: 10.1086/339329
  • 9
    Razonable RR, Rivero A, Rodriguez A et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184: 14611464.DOI: 10.1086/324516
  • 10
    Aubert G, Hassan-Walker AF, Madrigal JA et al. Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants. J Infect Dis 2001; 184: 955963.DOI: 10.1086/323354
  • 11
    Gratama JW, Van Esser JW, Lamers CH et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001; 98: 13581364.
  • 12
    Sester M, Gartner BC, Sester U, Girndt M, Mueller-Lantzsch N, Kohler H. Is the cytomegalovirus serologic status always accurate? A comparative analysis of humoral and cellular immunity. Transplantation 2003; 76: 12291230.DOI: 10.1097/01.TP.0000083894.61333.56
  • 13
    Schmidt CA, Oettle H, Peng R et al. Comparison of polymerase chain reaction from plasma and buffy coat with antigen detection and occurrence of immunoglobulin M for the demonstration of cytomegalovirus infection after liver transplantation. Transplantation 1995; 59: 11331138.
  • 14
    Marsano L, Perrillo RP, Flye MW et al. Comparison of culture and serology for the diagnosis of cytomegalovirus infection in kidney and liver transplant recipients. J Infect Dis 1990; 161: 454461.
  • 15
    Halling VW, Maine GT, Groettum CM et al. Clinical evaluation of a new recombinant antigen-based cytomegalovirus immunoglobulin M immunoassay in liver transplant recipients. Transplantation 2001; 71: 395397.DOI: 10.1097/00007890-200102150-00009
  • 16
    Falagas ME, Snydman DR, Ruthazer R, Werner BG, Griffith J. Surveillance cultures of blood, urine, and throat specimens are not valuable for predicting cytomegalovirus disease in liver transplant recipients. Clin Infect Dis 1997; 24: 824829.
  • 17
    Pellegrin I, Garrigue I, Ekouevi D et al. New molecular assays to predict occurrence of cytomegalovirus disease in renal transplant recipients. J Infect Dis 2000; 182: 3642.DOI: 10.1086/315688
  • 18
    Humar A, Gregson D, Caliendo AM et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 1999; 68: 13051311.DOI: 10.1097/00007890-199911150-00015